Survival Gains from Yervoy-Opdivo Combo
The Yervoy (ipilimumab) and Opdivo (nivolumab) combination improves long-term survival in advanced melanoma patients compared to Yervoy alone. In the phase 3 CheckMate 067 trial, after 10 years of follow-up, the combo achieved a 52% 10-year overall survival (OS) rate versus 39% with Yervoy monotherapy and 43% with Opdivo alone.[1][2] Median OS has not been reached for the combo group, with 52% of patients alive at 10 years.
Durability Across Melanoma Stages
For unresectable or metastatic melanoma, the combo yields sustained benefits: 52% OS at 10 years, 49.3% progression-free survival (PFS) rate at 7.5 years, and durable complete responses in 20% of patients lasting over a decade.[1][3] In adjuvant settings (resectable stage IIB-IV), the CheckMate 915 trial showed improved recurrence-free survival (RFS) hazard ratio of 0.75 versus Opdivo alone, with benefits persisting at 24 months.[4]
Benefits in Other Cancers
- Renal Cell Carcinoma (RCC): CheckMate 214 trial data at 42 months show 49% OS rate versus 38% for sunitinib, with 4-year OS at 49.3% for intermediate/poor-risk patients.[5]
- MSI-H/dMMR Cancers: CheckMate 142 reports 74% 3-year PFS and 73% OS across colorectal and non-colorectal tumors.[6]
- Esophageal Squamous Cell Carcinoma (ESCC): CheckMate 648 at 13 months median follow-up shows OS hazard ratio of 0.60 versus chemotherapy, with ongoing durability.[7]
These outcomes reflect the combo's mechanism: Opdivo blocks PD-1 to reactivate T-cells, while low-dose Yervoy inhibits CTLA-4 for broader immune priming, leading to deeper, longer responses than monotherapy.
How It Compares to Monotherapies Long-Term
| Treatment | 10-Year OS (Melanoma) | Median OS (Months, Melanoma) |
|-----------|-----------------------|------------------------------|
| Yervoy + Opdivo | 52% | Not reached [1] |
| Opdivo alone | 43% | 38.8 [2] |
| Yervoy alone | 39% | 22.3 [2] |
The combo reduces mortality risk by 42% versus Yervoy alone (hazard ratio 0.58).[1]
Ongoing Risks with Long-Term Use
While benefits endure, 10-year data show 52% grade 3-4 treatment-related adverse events, mainly immune-related (e.g., colitis, hepatitis), with 0.6% treatment-related deaths.[1] Long-term monitoring is needed for late-onset toxicities.
[1]: New England Journal of Medicine - 10-Year CheckMate 067 Outcomes
[2]: Bristol Myers Squibb Press Release - CheckMate 067 10-Year Data
[3]: ESMO 2022 - CheckMate 067 Update
[4]: NEJM - CheckMate 915 Adjuvant Trial
[5]: Lancet Oncology - CheckMate 214 42-Month Update
[6]: Annals of Oncology - CheckMate 142 3-Year Data
[7]: Lancet - CheckMate 648 Results